Do analysts recommend BYSI or NAGE?

Niagen Bioscience has a consensus target price of $10.50, suggesting a potential upside of 208.37%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Do analysts prefer BYSI or SRZN?

Surrozen has a consensus price target of $42.00, suggesting a potential upside of 91.70%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is BYSI or SRZN more profitable?

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Surrozen -4,810.50% N/A -154.08%

Do analysts prefer NKTX or BYSI?

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 337.88%. Given Nkarta's stronger consensus rating and higher probable upside, research analysts plainly believe Nkarta is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NKTX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% BeyondSpring N/A N/A -14.00%

Do analysts rate BYSI or ACIU?

AC Immune has a consensus price target of $7.50, suggesting a potential upside of 240.14%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is BYSI or ACIU more profitable?

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% AC Immune -1,788.02% -125.26% -40.85%

Do analysts recommend CHRS or BYSI?

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 503.95%. Given Coherus Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

BeyondSpring (BYSI) Competitors

$1.21 -0.04 (-3.28%)

As of 12:40 PM Eastern

Compare

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

Should you buy BeyondSpring stock or one of its competitors? MarketBeat compares BeyondSpring with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeyondSpring include Niagen Bioscience (NAGE), Surrozen (SRZN), Nkarta (NKTX), AC Immune (ACIU), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry.

How does BeyondSpring compare to Niagen Bioscience?

BeyondSpring (NASDAQ:BYSI) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Niagen Bioscience has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	28.41	-$1.01M	-$0.14	N/A
Niagen Bioscience	$129.42M	2.10	$17.38M	$0.21	16.21

In the previous week, Niagen Bioscience had 5 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Niagen Bioscience and 0 mentions for BeyondSpring. Niagen Bioscience's average media sentiment score of 0.38 beat BeyondSpring's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
BeyondSpring	Neutral
Niagen Bioscience	Neutral

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience has a consensus target price of $10.50, suggesting a potential upside of 208.37%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to BeyondSpring's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat BeyondSpring's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Niagen Bioscience	14.29%	22.68%	16.23%

Summary

Niagen Bioscience beats BeyondSpring on 14 of the 17 factors compared between the two stocks.

How does BeyondSpring compare to Surrozen?

BeyondSpring (NASDAQ:BYSI) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Surrozen had 2 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Surrozen and 0 mentions for BeyondSpring. Surrozen's average media sentiment score of 0.97 beat BeyondSpring's score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
BeyondSpring	Neutral
Surrozen	Positive

Surrozen has a consensus price target of $42.00, suggesting a potential upside of 91.70%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Surrozen	-4,810.50%	N/A	-154.08%

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BeyondSpring has higher earnings, but lower revenue than Surrozen. BeyondSpring is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	28.41	-$1.01M	-$0.14	N/A
Surrozen	$7.49M	33.94	-$242.03M	-$37.59	N/A

Summary

Surrozen beats BeyondSpring on 12 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Nkarta?

Nkarta (NASDAQ:NKTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

80.5% of Nkarta shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BeyondSpring has higher revenue and earnings than Nkarta. BeyondSpring is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
BeyondSpring	$1.75M	28.41	-$1.01M	-$0.14	N/A

Nkarta currently has a consensus price target of $10.75, indicating a potential upside of 337.88%. Given Nkarta's stronger consensus rating and higher probable upside, research analysts plainly believe Nkarta is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
BeyondSpring	N/A	N/A	-14.00%

Nkarta has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, Nkarta's average media sentiment score of 0.59 beat BeyondSpring's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Positive
BeyondSpring	Neutral

Summary

Nkarta beats BeyondSpring on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to AC Immune?

BeyondSpring (NASDAQ:BYSI) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled AC Immune'saverage media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
AC Immune	Neutral

BeyondSpring has higher earnings, but lower revenue than AC Immune. BeyondSpring is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	28.41	-$1.01M	-$0.14	N/A
AC Immune	$4.31M	52.07	-$85.03M	-$0.82	N/A

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

AC Immune has a consensus price target of $7.50, suggesting a potential upside of 240.14%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
AC Immune	-1,788.02%	-125.26%	-40.85%

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Summary

AC Immune beats BeyondSpring on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Coherus Oncology has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to BeyondSpring's net margin of 0.00%. BeyondSpring's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
BeyondSpring	N/A	N/A	-14.00%

Coherus Oncology has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.25	$168.02M	$1.67	0.86
BeyondSpring	$1.75M	28.41	-$1.01M	-$0.14	N/A

Coherus Oncology currently has a consensus price target of $8.67, indicating a potential upside of 503.95%. Given Coherus Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
BeyondSpring	Neutral

Summary

Coherus Oncology beats BeyondSpring on 10 of the 14 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.71M	$3.66B	$6.81B	$12.41B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-8.64	21.11	26.94	24.07
Price / Sales	28.41	165.92	487.97	87.33
Price / Cash	10.91	150.24	49.71	59.37
Price / Book	-2.05	8.11	10.44	6.20
Net Income	-$1.01M	$23.81M	$3.60B	$331.71M
7 Day Performance	-4.80%	-2.97%	-1.66%	-1.47%
1 Month Performance	-25.14%	-0.37%	0.63%	-2.03%
1 Year Performance	-35.35%	42.16%	23.07%	17.81%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.0293 of 5 stars	$1.21 -3.3%	N/A	-33.5%	$49.71M	$1.75M	N/A	80	Positive News Gap Up
NAGE Niagen Bioscience	4.343 of 5 stars	$3.37 -2.3%	$10.50 +211.6%	-63.9%	$268.40M	$130.42M	16.05	120
SRZN Surrozen	3.0555 of 5 stars	$22.88 -0.6%	$42.00 +83.6%	+164.3%	$265.64M	$3.48M	N/A	80
NKTX Nkarta	3.5558 of 5 stars	$3.67 +8.6%	$10.75 +192.9%	+34.4%	$262.55M	N/A	N/A	140
ACIU AC Immune	2.2099 of 5 stars	$2.52 -0.8%	$7.50 +197.6%	+10.6%	$256.47M	$3.70M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

How does BeyondSpring compare to Niagen Bioscience?

Summary

How does BeyondSpring compare to Surrozen?

Summary

How does BeyondSpring compare to Nkarta?

Summary

How does BeyondSpring compare to AC Immune?

Summary

How does BeyondSpring compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

How does BeyondSpring compare to Niagen Bioscience?

Which has better earnings and valuation, BYSI or NAGE?

Does the media prefer BYSI or NAGE?

Do institutionals and insiders hold more shares of BYSI or NAGE?

Do analysts recommend BYSI or NAGE?

Which has more volatility and risk, BYSI or NAGE?

Is BYSI or NAGE more profitable?

Summary

How does BeyondSpring compare to Surrozen?

Which has more risk and volatility, BYSI or SRZN?

Does the media refer more to BYSI or SRZN?

Do analysts prefer BYSI or SRZN?

Is BYSI or SRZN more profitable?

Do institutionals & insiders hold more shares of BYSI or SRZN?

Which has higher valuation & earnings, BYSI or SRZN?

Summary

How does BeyondSpring compare to Nkarta?

Do institutionals and insiders have more ownership in NKTX or BYSI?

Which has better valuation & earnings, NKTX or BYSI?

Do analysts prefer NKTX or BYSI?

Is NKTX or BYSI more profitable?

Which has more risk & volatility, NKTX or BYSI?

Does the media favor NKTX or BYSI?

Summary

How does BeyondSpring compare to AC Immune?

Does the media prefer BYSI or ACIU?

Which has stronger valuation and earnings, BYSI or ACIU?

Do insiders and institutionals hold more shares of BYSI or ACIU?

Do analysts rate BYSI or ACIU?

Is BYSI or ACIU more profitable?

Which has more volatility & risk, BYSI or ACIU?

Summary

How does BeyondSpring compare to Coherus Oncology?

Which has more volatility & risk, CHRS or BYSI?

Is CHRS or BYSI more profitable?

Which has preferable valuation & earnings, CHRS or BYSI?

Do analysts recommend CHRS or BYSI?

Do insiders & institutionals have more ownership in CHRS or BYSI?

Does the media favor CHRS or BYSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools